Kesimpta (Ofatumumab): What Its Used For, Dosing, and Side Effects

Kesimpta (ofatumumab) is a prescription injectable medication used to treat relapsing forms of multiple sclerosis (MS) in adults. It’s a targeted B-cell-depleting therapy, and it holds a distinction that sets it apart from most other high-efficacy MS treatments: it’s the only anti-CD20 therapy patients can inject themselves, at home, once a month, without needing an infusion center visit. This guide covers what Kesimpta treats, exactly how it works, the clinical trial evidence behind it, dosing and missed-dose guidance, the full side effect and monitoring picture, how it stacks up against other MS disease-modifying therapies, cost and insurance considerations, and the questions patients ask most often before and during treatment.

Table of Contents

What Is Kesimpta Used For?

Kesimpta is FDA-approved to treat relapsing forms of multiple sclerosis, a category that covers three specific presentations of the disease:

Clinically isolated syndrome (CIS) — a first episode of neurological symptoms caused by inflammation/demyelination, which may or may not go on to become MS
Relapsing-remitting MS (RRMS) — the most common form, marked by distinct attacks (relapses) followed by periods of partial or full recovery
Active secondary progressive MS (SPMS) — a later disease stage where relapses become less frequent but disability still accumulates, specifically when there is still measurable “active” inflammatory disease

Kesimpta is not approved for primary progressive MS (PPMS), a form of the disease that involves steady worsening from the start without distinct relapses. Ocrevus (ocrelizumab) is currently the only anti-CD20 therapy with FDA approval for PPMS — an important distinction when comparing the two drugs, since they’re often discussed side by side.

How Kesimpta Works

To understand how Kesimpta works, it helps to understand what’s going wrong in relapsing MS in the first place. MS is an autoimmune condition in which the immune system mistakenly attacks myelin — the protective, insulating coating around nerve fibers in the brain and spinal cord. B-lymphocytes (B-cells), a type of white blood cell, are now understood to play a central role in that attack: they present myelin-related proteins to other immune cells, produce inflammatory signaling molecules, and in some cases produce antibodies that contribute directly to nerve damage.

Kesimpta is a monoclonal antibody engineered to bind to a specific protein called CD20, found on the surface of certain B-cells (specifically pre-B and mature B-cells, but not the earliest stem-cell-stage or the most mature antibody-producing plasma cells). Once Kesimpta binds to a CD20-positive B-cell, it flags that cell for destruction by the body’s own immune defenses, through a combination of mechanisms including complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. The practical effect is a sharp, sustained drop in circulating CD20-positive B-cells within days of the first dose, which in turn reduces the inflammatory activity driving new MS relapses and new lesion formation on MRI.

Because Kesimpta spares the earliest B-cell precursors and the long-lived plasma cells that maintain existing antibody-based immunity (like protection from childhood vaccines), the intent behind this mechanism is to suppress the specific B-cell population implicated in MS activity while leaving more of the broader immune system intact than older, broader immunosuppressants would. That said, B-cell depletion of any kind still meaningfully raises infection risk, which is discussed in detail below.

Kesimpta does not repair myelin that has already been damaged, and it does not reverse disability that has already occurred. Like all current MS disease-modifying therapies, its goal is to reduce the frequency and severity of future relapses and slow the accumulation of new damage — not to cure the underlying disease.

Clinical Trial Evidence: The ASCLEPIOS Trials

Kesimpta’s FDA approval was based on two identically designed Phase 3 trials, ASCLEPIOS I and ASCLEPIOS II, which together enrolled 1,822 people with relapsing MS between the ages of 18 and 55. Participants were randomly assigned to receive either monthly Kesimpta injections or once-daily Aubagio (teriflunomide), an older oral MS medication, for up to 2.5 years. Neither patients nor investigators knew which drug a given participant was receiving (a double-dummy design), and the trials were run head-to-head against an active comparator rather than a placebo — a stronger, more clinically meaningful evidence standard.

The results favored Kesimpta clearly:

Annualized relapse rate — Kesimpta reduced the annualized relapse rate by 51% in one trial (0.11 vs. 0.22 with Aubagio) and 58% in the other (0.10 vs. 0.25)
Disability progression — Kesimpta significantly reduced the risk of confirmed disability worsening compared with Aubagio
MRI activity — Kesimpta patients had significantly fewer new or enlarging brain lesions on MRI over the trial period

Long-term follow-up data (from the ALITHIOS extension study, tracking patients for up to six years) reinforced the case for starting Kesimpta early rather than switching to it later: patients who began on Kesimpta from the start had 44% fewer relapses over six years compared with patients who started on Aubagio and switched to Kesimpta only after the initial trial period ended. This “early treatment” pattern is consistent with a broader trend in current MS research — that starting a highly effective therapy sooner, rather than escalating gradually, tends to produce better long-term outcomes for many patients.

How Kesimpta Is Given

Kesimpta is injected under the skin (subcutaneously) using a prefilled Sensoready autoinjector pen or a prefilled syringe. After proper training from a healthcare provider — typically administered under supervision for the first injection — most patients go on to give the injection themselves at home, commonly in the thigh, the outer area of the upper arm, or the abdomen (avoiding a 2-inch area around the navel).

Phase	Schedule
Loading dose	20 mg once weekly at weeks 0, 1, and 2
Maintenance dose	20 mg once monthly, starting at week 4

The three weekly loading doses are designed to bring B-cell counts down quickly; the once-monthly maintenance schedule then keeps them suppressed. Kesimpta pens and syringes need to be stored in a refrigerator, but can be left at room temperature for a limited window (check the specific product packaging) before use, and should never be left in direct sunlight, frozen, or shaken.

What to Do If You Miss a Dose

If a scheduled Kesimpta injection is missed, the general guidance (always confirm with the prescribing provider, since individual circumstances vary) is:

During the initial weekly loading doses: give the missed dose as soon as possible, then continue the original schedule from that point
During monthly maintenance dosing: give the missed dose as soon as remembered, then resume monthly dosing from the new date going forward, resetting the monthly clock to that injection

Patients should never double up on doses to “catch up,” and should call their prescriber’s office if there’s any uncertainty about timing.

Kesimpta Side Effects

The most commonly reported side effects in clinical trials were upper respiratory tract infections and headache. Other frequently reported effects include:

Injection-site reactions (redness, swelling, itching, or pain at the injection site)
Systemic injection-related reactions within 24 hours of a dose — fever, muscle aches, chills, or fatigue, most common and most pronounced after the very first injection, and generally becoming milder or disappearing with subsequent doses
Lower respiratory tract infections
Reduced immunoglobulin (antibody) levels with long-term, continuous use
Back pain

Serious Risks and Warnings

Because Kesimpta suppresses part of the immune system, it carries an increased risk of serious infections, some of which can be life-threatening. Specific warnings include:

Hepatitis B reactivation — B-cell depletion can allow a dormant hepatitis B infection to reactivate, sometimes causing serious liver damage. Providers screen for hepatitis B before starting treatment.
Progressive multifocal leukoencephalopathy (PML) — a rare but serious brain infection caused by the JC virus, which has occurred in patients on anti-CD20 therapies including ofatumumab. Any new or worsening neurological symptoms should be reported to a provider immediately, since early detection significantly affects outcomes.
Reduced vaccine effectiveness — because Kesimpta depletes B-cells, vaccines given during treatment may produce a weaker immune response. Live or live-attenuated vaccines are generally not recommended during treatment.

Because of these risks, providers typically check hepatitis B status and immunoglobulin levels before starting Kesimpta, then periodically monitor immunoglobulin levels and liver function during treatment. Vaccinations — especially any live vaccines — are generally brought up to date at least 4 weeks before starting Kesimpta whenever possible, since vaccinating during active B-cell depletion is both less effective and, for live vaccines, potentially riskier.

This is general information, not medical advice — anyone starting or currently on Kesimpta should follow their neurologist’s specific monitoring plan and report new or worsening neurological symptoms, signs of infection (fever, persistent cough, unusual fatigue), or symptoms of liver problems (yellowing skin or eyes, dark urine, unusual tiredness) right away.

Kesimpta During Pregnancy and Breastfeeding

There isn’t extensive controlled human data on Kesimpta use during pregnancy, though monoclonal antibodies in this class are known to cross the placenta, particularly later in pregnancy, and could affect a newborn’s B-cell counts and immune response to vaccines given in early infancy. Anyone who is pregnant, planning a pregnancy, or breastfeeding should discuss the risks and benefits of continuing or starting Kesimpta directly with their neurologist and OB/GYN — this is an individualized decision that depends on disease activity, prior treatment history, and personal risk tolerance, and isn’t something a general article can responsibly determine for a specific patient.

Kesimpta vs Other MS Disease-Modifying Therapies

Kesimpta is one of several high-efficacy disease-modifying therapies (DMTs) now available for relapsing MS. Here’s how it compares to the other options patients most commonly ask about.

Kesimpta vs Ocrevus (ocrelizumab)

Both are anti-CD20 B-cell-depleting antibodies, but they differ in a few important ways. Ocrevus is given as an intravenous infusion at an infusion center, typically every six months (after two initial doses two weeks apart); Kesimpta is self-injected at home once a month. Ocrevus is the only one of the two approved for primary progressive MS, while Kesimpta is approved only for relapsing forms. In indirect trial comparisons, Kesimpta has shown a somewhat greater reduction in annualized relapse rate, while the two drugs have shown broadly similar effects on confirmed disability progression. On cost, published U.S. list-price estimates put Ocrevus at roughly $65,000 per year compared with roughly $83,000 per year for Kesimpta, though actual out-of-pocket costs depend heavily on insurance coverage and manufacturer support programs. The practical trade-off many patients weigh is convenience and self-administration (Kesimpta) versus twice-yearly dosing that requires no monthly routine but does require infusion center visits (Ocrevus).

Kesimpta vs Tysabri (natalizumab)

Tysabri works through a completely different mechanism — it blocks immune cells from crossing into the brain and spinal cord, rather than depleting B-cells. It’s given as a monthly IV infusion at an infusion center. Tysabri carries a distinct and serious risk of PML that’s closely tied to JC virus antibody status, prior immunosuppressant use, and duration of treatment, which is why JC virus antibody testing is a standard part of the decision to start or continue Tysabri. Both drugs carry some PML risk, but the risk profile and monitoring approach differ enough that this comparison is very individualized and should be made with a neurologist familiar with the patient’s JC virus status and disease history.

Kesimpta vs Aubagio (teriflunomide)

Aubagio is an older oral MS medication (a once-daily pill) with a more modest efficacy profile than Kesimpta. This is the exact comparison used in the ASCLEPIOS trials described above, where Kesimpta significantly outperformed Aubagio on relapse rate, disability progression, and MRI activity. Aubagio remains an option for patients who prioritize a simpler oral regimen with a different risk profile over a higher-efficacy injectable, but head-to-head trial data clearly favors Kesimpta on efficacy.

Kesimpta Cost and Insurance

Kesimpta’s U.S. list price runs into the tens of thousands of dollars per year (published estimates put it around $83,000 annually), but list price is rarely what patients actually pay. Novartis, the manufacturer, offers a patient support program that includes copay assistance for commercially insured patients and other resources for people who are uninsured or underinsured. Because coverage, prior authorization requirements, and copay assistance eligibility vary significantly by insurance plan, the most reliable next step for any patient considering Kesimpta is to work directly with the prescribing neurologist’s office and the manufacturer’s support program to get an individualized cost estimate before starting treatment.

Frequently Asked Questions

Is Kesimpta a chemotherapy drug?

No. Kesimpta is a monoclonal antibody, not chemotherapy. It works by targeting a specific protein (CD20) on certain immune cells rather than broadly attacking rapidly dividing cells the way traditional chemotherapy drugs do. Some anti-CD20 antibodies, including a version of ofatumumab (marketed as Arzerra), are also used at much higher doses to treat certain blood cancers — but Kesimpta is a lower, specifically dosed formulation approved only for MS.

How long do you stay on Kesimpta?

Kesimpta is typically used as a long-term, ongoing treatment for relapsing MS, for as long as it continues to control disease activity and side effects remain manageable. Long-term trial data (through the ALITHIOS extension study) now covers up to six years of continuous use. Duration of treatment beyond that is an individual decision made with a neurologist, based on ongoing disease activity, MRI findings, and tolerability.

Can you drink alcohol while on Kesimpta?

There’s no specific drug interaction warning between alcohol and Kesimpta in the prescribing information, but patients should discuss alcohol use with their care team, particularly since liver function is already being monitored during treatment and heavy alcohol use can independently affect both liver health and MS symptoms like fatigue and balance.

Does Kesimpta lower white blood cell counts?

Kesimpta specifically depletes CD20-positive B-lymphocytes, a subset of white blood cells, rather than lowering the overall white blood cell count broadly. Providers monitor B-cell counts and immunoglobulin levels rather than a general white blood cell count to track the drug’s effect and assess infection risk.

What happens to B-cell counts after stopping Kesimpta?

B-cell counts generally begin to recover after Kesimpta is stopped, though the exact timeline for a given patient varies and should be discussed with a neurologist, particularly if a live vaccine or a switch to a different MS therapy is being planned after discontinuation.

Can Kesimpta be used with other MS medications?

Kesimpta is generally used as a standalone disease-modifying therapy rather than combined with another immune-modulating MS drug, since combining immunosuppressive therapies increases infection risk without established added benefit. Switching from one DMT to Kesimpta (or vice versa) typically involves a specific washout or overlap period depending on the prior medication, which a neurologist will plan individually.